Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
2009 · Breast Cancer Research and Treatment · 89 citations
https://doi.org/10.1007/s10549-009-0498-7